The World’s Top Cannabis Stock Provides Significant Appeal to Value Investors

Canopy Growth Corp.’s (TSX:WEED)(NYSE:CGC) international medical business operates primarily as a pharmacy model, with pharmacies being deemed essential businesses in Germany and other European countries.

| More on:
edit Cannabis leaves of a plant on a dark background

Image source: Getty Images

Canopy Growth (TSX:WEED)(NYSE:CGC) owns a Canadian medical business, which operates as an e-commerce channel. Canopy Growth’s international medical business operates primarily as a pharmacy model, with pharmacies being deemed essential businesses in Germany and other European countries in which the company conducts business while following applicable international and domestic legislation, regulations, and permits.

No material adverse impact of COVID-19

The COVID-19 pandemic, including government measures to limit the spread of COVID-19, did not appear to have a material adverse impact on Canopy Growth’s results of operations in the first quarter of fiscal 2022. However, there appears to be several uncertainties associated with the COVID-19 pandemic for Canopy Growth’s business model.

Potential uncertainties due to COVID-19

Uncertainties include those related to the distribution and acceptance of the vaccines and the effectiveness of the vaccines with respect to new variants of the virus. This could have an impact on the use of Canopy Growth’s products by consumers. Disruptions to the global and local economies due to related stay-at-home orders, quarantine policies, and restrictions on travel, trade, and business operations, and a reduction in discretionary consumer spending also has an impact on Canopy Growth’s business.

Significant ability to absorb any impacts and continue on a high-growth trajectory

Overall, the impact of the COVID-19 pandemic on Canopy Growth’s business, financial condition, results of operations, and cash flows appears quite uncertain at this stage. However, Canopy Growth should easily be able to absorb any impacts and continue on its high-growth trajectory.

Maintaining full operations and internal controls

In addition, since Canopy Growth’s non-production workforce continues to effectively work remotely using various technology tools, the company has been able to maintain full operations and internal controls over financial reporting and disclosures.

Solid balance sheet and excellent financial condition

Also, Canopy Growth has a solid balance sheet and is in excellent financial shape. Canopy Growth has sufficient liquidity available from cash and cash equivalents and short-term investments on hand of $560 million and $1.5 billion, respectively, at June 30, 2021, and from available capacity under the company’s revolving debt facility.

Significant ability to meet working capital and other operating requirements

This enables Canopy Growth to meet working capital and other operating requirements, fund growth initiatives and capital expenditures, settle the company’s liabilities, and repay scheduled principal and interest payments on debt for at least the next 12 months.

Growth by acquisition

Recently, Canopy Growth implemented a plan of arrangement with Acreage Holdings, a United States multi-state cannabis operator. Canopy Growth agreed to acquire approximately 70% of the issued and outstanding shares of Acreage and obtained the right to acquire the other 30% of Acreage.

Pathway into lucrative cannabis markets

This was an excellent move by Canopy Growth. The acquisition of Acreage should provide it a pathway into the lucrative cannabis markets in the United States. However, Canopy Growth and Acreage plan to continue to operate as independent companies until the acquisition of Acreage is completed. Additionally, Canopy Growth has built a hemp supply chain in the United States, which provides it with further growth opportunities.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

The Motley Fool has no position in any of the stocks mentioned. Fool contributor Nikhil Kumar has no position in any of the stocks mentioned. 

More on Coronavirus

eat food
Coronavirus

Goodfood Stock Doubles Within Days: Time to Buy?

Goodfood (TSX:FOOD) stock has surged 125% in the last few weeks, so what happened, and should investors hop back on…

Read more »

stock data
Tech Stocks

If I Could Only Buy 1 Stock Before 2023, This Would Be It

This stock is the one company that really doesn't deserve its ultra-low share price, so I'll definitely pick it up…

Read more »

Aircraft Mechanic checking jet engine of the airplane
Coronavirus

Air Canada Stock Fell 5% in November: Is it a Buy Today?

Air Canada (TSX:AC) stock saw remarkable improvements during its last quarter but still dropped 5% with more recession hints. So,…

Read more »

Airport and plane
Coronavirus

Is Air Canada Stock a Buy Today?

Airlines are on the rebound. Does Air Canada stock deserve to be on your buy list?

Read more »

A patient takes medicine out of a daily pill box.
Coronavirus

Retirees: 2 Healthcare Stocks That Could Help Set You up for Life

Healthcare stocks offer an incredible opportunity for growth for those investors who look to the right stocks, such as these…

Read more »

sad concerned deep in thought
Coronavirus

Here’s Why I Just Bought WELL Health Stock

WELL Health stock (TSX:WELL) may be a healthcare stock and a tech stock, but don't let that keep you from…

Read more »

healthcare pharma
Coronavirus

WELL Stock: The Safe Stock Investors Can’t Afford to Ignore

WELL stock (TSX:WELL) fell 68% from peak to trough, and yet there's no good reason as to why. So now…

Read more »

telehealth stocks
Tech Stocks

The Ultimate Growth Stock to Buy With $100 Right Now

After climbing 600%, this growth stock is now down 68%. But it won't be long before other investors catch on.

Read more »